The Directory of Pharma Companies and News


ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company’s pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market. ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR). Early 2017, ThromboGenics started a Phase II clinical study evaluating THR- 317, a PIGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was inlicensed from Galapagos, are in late stage pre-clinical development. ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Novartis commercializes JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Category: Biotech
Category: Biotech

Thrombogenics News

2015-08-26ThromboGenics Business Update H1 2015
2015-07-20Regulated Information - Transparency Statement
2015-06-26Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor
2015-05-20ThromboGenics Q1 2015 Business Update
2015-05-19Transparency Statement - Philippe Baron Vlerick 3.6% shareholding
2015-04-23ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO)
2015-04-21Transparency Statement - Norges Bank 2.98% shareholding
2015-04-14ThromboGenics and VIB launch New Oncology Company Oncurious NV to develop TB-403 for Pediatric Brain Tumors
2015-04-03Transparency Statement - Norges Bank 2,95% shareholding
2015-03-24ThromboGenics Announces Positive Topline Results from OASIS Study
2015-03-16ThromboGenics’ JETREA® Gains Approval in Brazil
2015-03-12ThromboGenics Full Year 2014 Business Update
2015-03-05ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor
2015-03-02ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA®
2015-02-12ThromboGenics’ JETREA® Gains Further Approvals
2015-02-05Thrombogenics Awarded €1.1 million IWT Research Grant
2015-01-22Norges Bank notified 3.03% shareholding in ThromboGenics NV
2015-01-22ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director
2015-01-07ThromboGenics Appoints Dominique Vanfleteren as new Chief Financial Officer
2014-12-22ThromboGenics to Present at the J.P. Morgan Annual Healthcare Conference 2015 in San Francisco
2014-11-06ThromboGenics Q3 Business Update 2014
2014-10-14ThromboGenics’ Commitment to the US Retina Community Highlighted at American Academy of Ophthalmology 2014 Meeting
2014-10-06ThromboGenics’ JETREA® Gains Approval in Australia
2014-09-02ThromboGenics’ JETREA® Gains Approval in Taiwan
2014-09-01ThromboGenics’ JETREA® Receives Reimbursement in Spain
2014-08-28ThromboGenics Business Update H1 2014
2014-08-11ThromboGenics’ JETREA® Receives Positive Recommendation from Scottish Medicines Consortium (SMC)
2014-07-31ThromboGenics’ JETREA® Nominated for 2014 Prix Galien USA
2014-07-03ThromboGenics´ JETREA® Gains Approval in Singapore
2014-07-01ThromboGenics’ JETREA® Gains First Latin American Approval in Uruguay
2014-06-24ThromboGenics Provides Update on Strategic Review Process - Company to Remain Independent - CFO and Board Member Chris B...
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.
E_CORE_WARNING Error in file Unknown at line 0: PHP Startup: Invalid library (appears to be a Zend Extension, try loading using from php.ini)